- Home
- XENE vs VKTX Comparison
XENE vs VKTX Comparison
Compare XENE & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XENE | VKTX |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | XENE | VKTX |
|---|---|---|
| Price | $43.91 | $35.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $53.91 | ★ $87.07 |
| AVG Volume (30 Days) | 754.3K | ★ 2.4M |
| Earning Date | 11-03-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.74 | $18.92 |
| 52 Week High | $46.60 | $43.55 |
Technical Indicators
Market Signals| Indicator | XENE | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 46.83 |
| Support Level | $43.41 | $34.67 |
| Resistance Level | $46.36 | $37.83 |
| Average True Range (ATR) | 1.32 | 1.44 |
| MACD | -0.11 | -0.11 |
| Stochastic Oscillator | 37.28 | 32.65 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.